Misplaced Pages

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Brimarafenib

Clinical data
Other names	BGB-3245
Identifiers
IUPAC name 1--1a,6b-dihydro-1H-cyclopropabenzofuran-1-yl]-3-(2,4,5-trifluorophenyl)urea
CAS Number	1643326-82-2
PubChem CID	117807031
IUPHAR/BPS	13203
UNII	GXS33OY2CB
Chemical and physical data
Formula	C24H17F3N4O4
Molar mass	482.419 g·mol
3D model (JSmol)	Interactive image
SMILES C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O545NC(=O)NC6=CC(=C(C=C6F)F)F
InChI InChI=InChI=1S/C24H17F3N4O4/c25-13-8-15(27)16(9-14(13)26)29-24(33)31-21-20-12-7-10(1-3-17(12)35-22(20)21)34-18-5-6-28-23-11(18)2-4-19(32)30-23/h1,3,5-9,20-22H,2,4H2,(H,28,30,32)(H2,29,31,33)/t20-,21-,22-/m0/s1 Key:USMWOBMHNWNPAP-FKBYEOEOSA-N

Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.

It is being developed by MapKure, LLC, a joint venture between SpringWorks Therapeutics and BeiGene.

References

1. ^ "Brimarafenib".
2. Tellenbach FL, Seiler LL, Johnson M, Rehrauer H, Schukla P, Martinez-Gomez J, et al. "Combination of the Novel Raf Dimer Inhibitor Brimarafenib with the Mek Inhibitor Mirdametinib is Effective Against Nras Mutant Melanoma". SSRN: 4934723. doi:10.2139/ssrn.4934723.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antineoplastic drugs
• Benzofurans
• Ethers
• Fluorobenzenes
• Naphthyridines
• Phenols
• Piperidinones
• Ureas
• Pharmacology stubs